Article
Oncology
Wenjing Zhang, Zhijuan Lin, Fuyan Shi, Qiang Wang, Yujia Kong, Yanfeng Ren, Juncheng Lyu, Chao Sheng, Yuting Li, Hao Qin, Suzhen Wang, Qinghua Wang
Summary: Immune checkpoint inhibitors significantly improve the survival outcomes of advanced melanoma and non-small cell lung cancer. This study identifies HSPG2 mutations as potential clinical biomarkers for evaluating the efficacy of immune checkpoint inhibitor therapy. HSPG2 mutations are associated with favorable tumor immunogenicity and immunotherapeutic efficacy.
Article
Multidisciplinary Sciences
Jean Ching-Yi Tien, Seema Chugh, Andrew E. Goodrum, Yunhui Cheng, Rahul Mannan, Yuping Zhang, Lisha Wang, Vijaya L. Dommeti, Xiaoming Wang, Alice Xu, Jennifer Hon, Carson Kenum, Fengyun Su, Rui Wang, Xuhong Cao, Sunita Shankar, Arul M. Chinnaiyan
Summary: The study demonstrates a pathogenic role for AGO2 in KRAS-dependent non-small cell lung cancer, suggesting that its knockout may help inhibit tumor growth and improve pathological grade.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Biochemistry & Molecular Biology
Liping Zhu, Dafu Ye, Tianyu Lei, Jie Wu, Wei Wang, Bin Xu
Summary: Although immune checkpoint inhibitors (ICIs) have shown remarkable efficacy in treating non-small cell lung cancer (NSCLC), it is challenging to accurately predict which patients will respond to ICIs using conventional criteria. Previous studies have suggested that specific gene mutations may play a role in immunotherapy response, but the predictive value of single gene mutations may be limited. With advances in sequencing technology, it has been discovered that multiple mutations often co-occur and can synergistically affect signaling pathways involved in anti-tumor immune responses. Therefore, the mutation profile, especially co-mutations, of patients may be an important consideration for predicting the efficacy of ICIs.
EXPERT REVIEWS IN MOLECULAR MEDICINE
(2022)
Article
Oncology
Wenjing Zhang, Fuyan Shi, Yujia Kong, Yuting Li, Chao Sheng, Suzhen Wang, Qinghua Wang
Summary: Through integration of multiple studies, our research revealed a significant correlation between PTPRT mutations and the efficacy of ICI treatment in melanoma and NSCLC patients. Mutated patients showed better response rates and prolonged survival in immunotherapy, along with higher immune infiltration and mutation burden.
Article
Medicine, General & Internal
Fang Hao
Summary: Despite advances in diagnosis and treatment, lung cancer remains one of the most deadly human diseases, with a poor survival rate for patients with advanced metastatic disease. The study found that KDM5B/C were overexpressed in LUAD and LUSC, positively correlated with overall survival and CD4+ T cells infiltration. Additionally, KDM5 subfamily overexpression was associated with inflammatory and wound healing subtypes in lung cancer.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Geriatrics & Gerontology
Hailun Xie, Guotian Ruan, Lishuang Wei, Li Deng, Qi Zhang, Yizhong Ge, Mengmeng Song, Xi Zhang, Shiqi Lin, Xiaoyue Liu, Ming Yang, Chunhua Song, Xiaowei Zhang, Hanping Shi
Summary: This study compared the performance of existing haematological systemic inflammation biomarkers in predicting the prognosis of NSCLC patients and found that the inflammatory burden index (IBI) is the optimal systemic inflammation biomarker for predicting the prognosis of NSCLC patients. The IBI is associated with overall survival, 90-day outcomes, length of hospitalization, hospitalization expenses, and cachexia in NSCLC patients.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Article
Biochemistry & Molecular Biology
Yihong Ren, Yuxin Zhao, Yanan Shan, Sixuan Li, Nan Su, Zhigang Cui, Zhihua Yin
Summary: This study found that hsa_circ_0049657, a circular RNA derived from the NFIX gene, was down-regulated in NSCLC tissues and cells. In addition, we could suppress the proliferation and invasion abilities and promote apoptosis of NSCLC cells by up-regulating hsa_circ_0049657.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biotechnology & Applied Microbiology
Fan Yang, Chunlan Ma, Jing Qiu, Xiaoli Feng, Kai Yang
Summary: This study identified 114 circRNAs that were differentially expressed in NSCLC tissue compared to paracancerous tissue levels, with 77 downregulated and 37 upregulated. CircRNA_001846 may serve as a promising diagnostic biomarker for NSCLC, associated with tumor differentiation, lymph node metastasis, and node metastasis stage.
Article
Oncology
Xinan Wang, Biagio Ricciuti, Tom Nguyen, Xihao Li, Michael S. Rabin, Mark M. Awad, Xihong Lin, Bruce E. Johnson, David C. Christiani
Summary: This study investigates the relationship between smoking history and clinically relevant mutations in lung cancer patients, revealing a significant dose-response association between smoking history and genetic alterations in cancer-related pathways and tumor mutation burden in advanced lung adenocarcinoma.
Review
Biochemistry & Molecular Biology
Mariafrancesca Hyeraci, Elena Sofia Papanikolau, Marta Grimaldi, Francesco Ricci, Sabatino Pallotta, Rosanna Monetta, Ylenia Aura Minafo, Giovanni Di Lella, Giovanna Galdo, Damiano Abeni, Luca Fania, Elena Dellambra
Summary: Non-melanoma skin cancers (NMSCs) are the most common cancer diseases in the Caucasian race, with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and actinic keratosis (AK) being the main types. Proper prevention through photoprotection, which can be topical or systemic, is crucial due to the individual and social burdens of skin cancers. UV ray exposure is a major risk factor, and molecules with antioxidant, anti-inflammatory, or immunomodulator mechanisms have shown effectiveness in preventing NMSC, although no compound has been proven to prevent malignant melanoma (MM). This review provides clinical and preclinical data on commonly used compounds for systemic photoprotection.
Article
Oncology
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyurek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan Sayin
Summary: This retrospective study investigated the impact of KRAS mutational status on clinical outcome in patients with metastatic non-small cell lung cancer (NSCLC). The results showed that KRAS(MUT) patients had better response to immune checkpoint blockade (ICB) but worse response to platinum doublet chemotherapy (PT). Additionally, KRAS(WT) patients with high PD-L1 expressing tumors responded better to PT than ICB.
Article
Biochemistry & Molecular Biology
Evelyn de Andrade Salomao, Valter Aragao do Nascimento, Caio Fernando Ramalho de Oliveira, Iandara Schettert Silva, Rita de Cassia Avellaneda Guimaraes, Danielle Bogo
Summary: This study aims to analyze the behavior of the fluorescent marker IR-780 in melanoma cells and evaluate its application in vitro and in vivo. The results showed that IR-780 had limited efficacy in evaluating tumor growth but was effective in diagnosing pulmonary metastatic tumors.
Review
Immunology
Yang Ge, Ting Ye, Siyun Fu, Xiaoying Jiang, Hang Song, Bin Liu, Guoquan Wang, Jinghui Wang
Summary: Lung cancer, especially non-small cell lung cancer (NSCLC), is a severe and common type of cancer worldwide. NSCLC is typically treated with surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. However, immunotherapy still faces challenges, such as poor response rates and uncertainty in identifying effective populations. This review focuses on the role of extracellular vesicles (EVs) as biomarkers in NSCLC immunotherapy and discusses their definition, properties, and different components as potential biomarkers. It also explores the interaction between EVs as biomarkers and novel approaches or concepts in NSCLC immunotherapy research, providing insights for improving the benefits of immunotherapy for NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
M. Stares, T. E. Ding, C. Stratton, F. Thomson, M. Baxter, H. Cagney, K. Cumming, A. Swan, F. Ross, C. Barrie, K. Maclennan, S. Campbell, T. Evans, A. Tufail, S. Harrow, H. Lord, B. Laird, M. MacKean, I Phillips
Summary: This study evaluated the prognostic significance of biomarkers of the systemic inflammatory response in patients with advanced non-small-cell lung cancer (NSCLC) receiving first-line pembrolizumab. The results showed that albumin and neutrophil count were independently associated with progression-free survival (PFS) and overall survival (OS). A simple score combining these biomarkers, called Scottish Inflammatory Prognostic Score (SIPS), was developed and found to predict survival in NSCLC patients. SIPS can stratify survival and assist clinicians and patients with treatment decisions.
Article
Immunology
Zedong Jiang, Yao Zhou, Juan Huang
Summary: The study proposes a combinatorial strategy for predicting response to immune checkpoint blockade therapy in lung cancer, validating its efficacy in an independent cohort of NSCLC patients. The constructed ICB treatment signature (ITS) significantly correlates with progression-free survival and treatment response, outperforming traditional biomarkers like TMB and PD-L1. Moreover, the ITS score exhibits predictive power in other cancer datasets, indicating its scalability and robustness in predicting ICB treatment response.
FRONTIERS IN IMMUNOLOGY
(2021)